aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Frequently asked questions
What sector does aTyr Pharma, Inc. (ATYR) operate in?
aTyr Pharma, Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is aTyr Pharma, Inc. (ATYR) current stock price?
As of the latest data, aTyr Pharma, Inc. stock price is $0.51, with a previous close of $0.50. aTyr Pharma, Inc. gained $0.01 in the last trading session, representing a 1.79% increase.
What is aTyr Pharma, Inc. (ATYR) current market capitalization?
aTyr Pharma, Inc. market cap is approximately 50.10 million.
What is aTyr Pharma, Inc. (ATYR) Earnings Per Share (EPS)?
The trailing EPS is -$0.74, and the forward EPS is -$0.61.
What is aTyr Pharma, Inc. (ATYR) EBITDA?
aTyr Pharma, Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -10.88 million.
Does aTyr Pharma, Inc. (ATYR) pay dividends?
No. aTyr Pharma, Inc. does not pay a dividend.
What is aTyr Pharma, Inc. (ATYR) beta (volatility) score?
aTyr Pharma, Inc. has a beta of 0.518, indicating lower volatility than the overall market.
